Scholarlink

Background <p>Phenylketonuria (PKU) is an autosomal recessive disorder caused by PAH alterations, leading to elevated phenylalanine (Phe) and neurotoxicity. Newborn screening (NBS) and early therapy improve outcomes. This study aimed to characterize the molecular and phenotypic spectrum of PKU, explore genotype–phenotype correlations, and evaluate the relationship between PAH variants and BH4 responsiveness to guide personalized treatment.</p> Methods <p>Medical and genetic records of 171 patients diagnosed with hyperphenylalaninemia via NBS were reviewed. Demographic data, diagnostic Phe and tyrosine (Tyr) levels, BH4 loading test results, and genetic analyses including Sanger sequencing, MLPA, and array CGH were assessed. Allelic and genotype–phenotype values were used to estimate variant severity.</p> Results <p>168 carried ≥ 1 PAH variant; three had BH4 metabolism disorders. A total of 63 distinct PAH variants were identified; MLPA detected large deletions in three patients. Five variants (c.1066-11G &gt; A, c.782G &gt; A, c.143T &gt; C, c.898G &gt; T, c.1208&#xa0;C &gt; T) accounted for &gt; 50% of the cohort. Among 100 patients tested, 41% responded to BH4, with c.782G &gt; A most common (21%). Overall, 68.5% received dietary and/or BH4 therapy.</p> Conclusion <p>This study contributes to our understanding of PKU’s molecular and phenotypic landscape, highlighting the importance of utilising both genotype and response to the BH4 loading test in the design of personalised treatments, beyond the initial Phe level.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genotype–phenotype correlations in phenylketonuria: PAH variants and BH4 responsiveness for treatment design

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月21日

查看全文
  • Meryem Karaca,
  • Asuman Gedikbasi,
  • Arzu Selamioğlu,
  • Alihan Yesil,
  • Guven Toksoy,
  • Cagri Gulec,
  • Mehmet Cihan Balci,
  • Dilek Güneş,
  • Behiye Tuğçe Yıldırım,
  • Gizem Kına,
  • Volkan Karaman,
  • Ayca Dilruba Aslanger,
  • Birsen Karaman,
  • Mubeccel Demirkol,
  • Zehra Oya Uyguner,
  • Gulden Fatma Gokcay

摘要

Background

Phenylketonuria (PKU) is an autosomal recessive disorder caused by PAH alterations, leading to elevated phenylalanine (Phe) and neurotoxicity. Newborn screening (NBS) and early therapy improve outcomes. This study aimed to characterize the molecular and phenotypic spectrum of PKU, explore genotype–phenotype correlations, and evaluate the relationship between PAH variants and BH4 responsiveness to guide personalized treatment.

Methods

Medical and genetic records of 171 patients diagnosed with hyperphenylalaninemia via NBS were reviewed. Demographic data, diagnostic Phe and tyrosine (Tyr) levels, BH4 loading test results, and genetic analyses including Sanger sequencing, MLPA, and array CGH were assessed. Allelic and genotype–phenotype values were used to estimate variant severity.

Results

168 carried ≥ 1 PAH variant; three had BH4 metabolism disorders. A total of 63 distinct PAH variants were identified; MLPA detected large deletions in three patients. Five variants (c.1066-11G > A, c.782G > A, c.143T > C, c.898G > T, c.1208 C > T) accounted for > 50% of the cohort. Among 100 patients tested, 41% responded to BH4, with c.782G > A most common (21%). Overall, 68.5% received dietary and/or BH4 therapy.

Conclusion

This study contributes to our understanding of PKU’s molecular and phenotypic landscape, highlighting the importance of utilising both genotype and response to the BH4 loading test in the design of personalised treatments, beyond the initial Phe level.